NEW YORK, July 29, 2026, 05:58 EDT
- The stock rose 54.5% to $4.25 before the bell, after ending Tuesday’s session at $2.75.
- According to Tuesday’s filing, there was $5.1 million in cash on hand and 971,043 shares outstanding.
- The newly issued warrant shares represent 88.3% of the existing number of company shares.
Autonomix Medical shares jumped ahead of Wednesday’s market open following a balance-sheet update that revealed a significant valuation disparity. Nasdaq trading was shut during regular hours. By 5:55 a.m., premarket volume totaled 3.31 million shares .
Based on Tuesday’s closing figures, the revised share total suggested a $2.67 million market capitalisation. The reported cash stood at $5.1 million, translating to roughly $5.25 per share. Gross cash was therefore 91% higher than the closing share price.
The premarket surge reduced but did not close the gap. Shares were at $4.25, which remained roughly 19% under gross cash per share. Gross cash does not represent liquidation value.
The cash bridge provides a starker alert. Autonomix reported $7 million in cash as of March 31. A subsequent warrant exercise in July generated roughly $2.6 million gross, but by July 28, cash levels were around $5.1 million.
Based on the provided figures, net cash usage in other areas totaled around $4.5 million across 119 days. That equates to a preliminary rate close to $1.1 million each month. This amount could cover financing expenses and additional cash flows.
An alternate approach yields a comparable outcome. Operating cash use for fiscal 2026 totaled $12.3 million. Using this rate to divide present cash indicates about five months of runway. This early estimate does not represent company guidance.
| Filing-based comparison | Current basis | If all Series D warrants executed |
|---|---|---|
| Cash balance | $5.1 million | About $10.0 million |
| Shares outstanding | 971,043 | 1,828,505 |
| Gross cash per share | About $5.25 | About $5.49 |
| Runway at fiscal 2026 operating burn | About 5.0 months | About 9.8 months |
| Incremental shares | — | 857,462, or 88.3% |
Initial calculations are based on all warrants being exercised in cash at $5.75, not accounting for liabilities, exercise fees, or post-July 28 cash outflows. Autonomix stated that warrant exercises are not guaranteed.
The table illustrates how the warrant package can have mixed effects. Exercising in full for cash may generate $4.9 million, but it would also increase the share count by 88.3%.
The S-3 does not represent a new primary offering of stock. Instead, it covers the resale of shares tied to two Series D warrants. Autonomix gains funds only when the warrants are exercised, not from later resale of those shares.
The number of shares has grown. Following June’s reverse split, it climbed 79% from 542,349. This gain was due to the July exercise of 428,731 existing warrants.
The newly issued warrants have a strike price of $5.75 and a term of 5.5 years. The shares traded 26% under that strike in early Wednesday trading. As a result, the timing for possible exercise is not clear.
MarketWatch data indicated heavy activity before trading began, with 10.6 million shares changing hands Tuesday—26.8 times higher than the 65-day average volume. Despite the surge, AMIX was still down 30.9% across five sessions entering Wednesday.
The operating case is still in its initial phase. On July 24, an animal study observed renal neural signals both pre- and post-targeted ablation. Chief Executive Brad Hauser described the results as “a critical milestone” for sensing and localization. GlobeNewswire
Autonomix’s platform is still investigational and does not have marketing authorization in the U.S. Enrollment for the expansion study was halted following inconsistent early clinical results. Management projects that an additional $25 million to $32 million will be required ahead of the first commercial launch.
This week will reveal if cash value surpasses supply from financing. The primary range is tighter than usual: $5.25 gross cash for each share versus a warrant strike price of $5.75. Regular-session flows will dictate if gains made on Wednesday continue to hold.
Risks: The cash-per-share number does not factor in liabilities or anticipated expenditures. Autonomix has not launched any approved products, generates no revenue, and faces a going-concern notice. The stock could be impacted by warrant exercises, setbacks in clinical progress, or any new round of funding.
